fa تحقيقي Original Paper <div><strong>ABSTRACT</strong><br> <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Background and Objectives</strong>: C-C chemokine receptor type 5 (CCR5) is a chemokine receptor expressed at high levels on the surface of T-cells. A 32-bp deletion in the coding region of the CCR5 (CCR5&Delta;32) leads to production of an incomplete protein that is not expressed on the cell surface. CCR5&Delta;32 may be involved in development of autoimmune disease, such as systemic lupus erythematosus. We investigated frequency of the CCR5&Delta;32 polymorphism in SLE patients and healthy controls, and evaluated the relationship between the CCR5&Delta;32 polymorphism and susceptibility to SLE in Golestan Province, Iran.<br> <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methods:</strong> Whole blood samples were taken from 80 SLE patients admitted to Shahid Sayyad Shirazi hospital and 80 healthy controls (from a blood bank) in the Golestan Province, in 2016. Baseline clinical and laboratorial characteristics were evaluated regarding the CCR5&Delta;32 genotypes. The CCR5&Delta;32 polymorphism was determined from genomic DNA by polymerase chain reaction.<br> <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Result: </strong>Genotype frequencies of both groups were in the Hardy-Weinberg equilibrium. The frequencies of the CCR5 and the CCR5&Delta;32 alleles were 98.13% and 1.88% among the patients, and 98.75% and 1.25% among the controls, respectively. Homozygote CCR5&Delta;32 was not observed in the subjects. The frequency of heterozygous &Delta;32 was 3.8% and 2.5% among the SLE patients and controls, respectively (P-value>0.05). There was no significant association between the CCR5 status and clinical signs of SLE (P>0.05)<span dir="RTL">.</span><br> <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conclusion</strong>: Our data suggest that the CCR5&Delta;32 polymorphism has no correlation with SLE in our study population. In addition, the frequency of the &Delta;32 polymorphism in SLE patients and controls does not follow the Hardy-Weinberg equilibrium<br> <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;Keywords: </strong>CCR5, Homozygote CCR5&Delta;32, Heterozygote CCR5&Delta;32, CCR5&Delta;32 allele, SLE.</div> CCR5, Homozygote CCR5Δ32, Heterozygote CCR5Δ32, CCR5Δ32 allele, SLE. 38 43 http://mlj.goums.ac.ir/browse.php?a_code=A-10-1-515&slc_lang=fa&sid=1 Zahra Heydarifard 100319475328460014269 100319475328460014269 No Research Committee Student, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran Alijan Tabarraei Tabarraei@goums.ac.ir 100319475328460014270 100319475328460014270 Yes Infectious Disease Research Center, Golestan University of Medical Sciences, Gorgan, Iran Nafiseh Abdollahi 100319475328460014271 100319475328460014271 No Bone, Joint and Connective Tissue Research Center, Golestan University of Medical Sciences, Gorgan, Iran Abdolvahab Moradi 100319475328460014272 100319475328460014272 No Infectious Disease Research Center, Golestan University of Medical Sciences, Gorgan, Iran Yosef Khanjari 100319475328460014273 100319475328460014273 No Research Committee Student, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran